Bile acids have been traditionally viewed as detergent molecules involved in the solubilization and absorption of lipids and lipid-soluble vitamins from the intestines. However, as a result of intensive research over the past two decades, bile acids are now viewed as endocrine signaling molecules that activate specific nuclear receptors and G-protein coupled receptors regulating nutrient metabolism in the liver and intestines. The year 2015 marks the 20-year anniversary of the cloning and discovery of farnesoid X receptor (NR4H1; FXR). FXR is a main bile acid nuclear receptor and plays an essential role in the regulation of bile acids, lipids, glucose and drug metabolism, as well as inhibiting inflammation and suppressing carcinogenesis in the liver and intestine. Bile acids also activate pregnane X receptor, constitutive androstane receptor, vitamin D receptor, G protein\--coupled bile acid receptor (TGR5), and sphingosine-1-phosphate receptor 2 (S1PR2) to regulate growth and functions of hepatocytes, cholangiocytes and enterocytes. Moreover, bile acids also induce, *via* FXR, critical regulators of metabolism, inflammation and carcinogenesis in the liver and intestine, including small heterodimer partner (SHP) and fibroblast growth factor 15/19 (FGF15/19). The regulation of bile acid homeostasis is subject to traditional gene promoter regulation, posttranscriptional modulation and epigenetic regulation.

Historically, bile acids have been used as medicines around the world. Identification of new signaling pathways mediated by bile acids and bile acid derivatives should result in optimizing the current standard therapy for hepatic disorders and developing novel therapeutic targets for various liver diseases and metabolic syndrome.

In this issue, we have gathered leading experts in bile acid research around the world to provide the most comprehensive and timely review of bile acids, their receptors and regulated pathways/functions with a focus on liver and the gastrointestinal area. These in-depth reviews will provide the researchers, clinicians and pharmaceutical entrepreneurs the background knowledge for targeting bile acid\--mediated signaling pathways to prevent and treat hepatic, intestinal, and metabolic disorders.
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